Kinfo
Lucid Diagnostics Inc. logo

Lucid Diagnostics Inc.

LUCDNASDAQHealthcare·US · USD
$0.45
+0.03 (+7.93%)
Prices as of November 13, 2026 · market closed

Price

Key statistics

Valuation
Market cap85.74M USD
Enterprise value63.26M USD
Trailing P/E-1.05
Forward P/E-2.40
PEG ratio-2.40
Price / sales14.60
Price / book7.58
Profitability
Gross margin1.97%
Operating margin-930.82%
Profit margin-41.73%
Return on assets-81.63%
Return on equity-556.27%
Income (TTM)
Revenue5.45M USD
Gross profit-1.18M USD
EBITDA-49.81M USD
Net income-65.01M USD
Diluted EPS-$0.44
Rev. growth (YoY)26.70%
Balance sheet
Total cash34.47M USD
Total debt24.91M USD
Debt / equity227.96
Current ratio1.33
Book value / share-$0.33
Cash flow (TTM)
Operating cash flow-46.87M USD
Levered free cash flow-26.43M USD
Shares & price
Shares outstanding190.76M
Float140.76M
Held by institutions32.36%
Beta1.16
50-day MA$0.62
200-day MA$0.99
52-week high$1.63
52-week low$0.30
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-12-0.05-0.06−20.00%2026-05-13-0.06-0.07−16.67%2026-03-25-0.09-0.10−11.11%2026-02-242.522.72+7.94%2025-11-12-0.09-0.10−11.11%
About Lucid Diagnostics Inc.

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on the early detection of esophageal precancer and cancer in patients with gastroesophageal reflux disease, or GERD. Its core offering centers on the EsoGuard Esophageal DNA Test, which is performed using samples collected with the EsoCheck Esophageal Cell Collection Device to help identify at-risk patients before disease progresses. The company’s products are designed for use in clinical settings and support physicians in screening patients who may benefit from further evaluation. Lucid Diagnostics serves the healthcare market by addressing an important unmet need in cancer prevention and risk assessment, particularly for a condition linked to highly lethal esophageal adenocarcinoma. The company is headquartered in New York, New York, and operates as a subsidiary of PAVmed Inc.

Sector
Healthcare
Industry
Medical Devices
CEO
Dr. Lishan Aklog M.D.
Employees
82
Headquarters
New York, NY, United States

Frequently asked questions about Lucid Diagnostics Inc.